Program
4CMenB vaccine
Also written as “rLP2086”, “rMenB+OMV NZ” and “Meningococcal B vaccine”.
In GlaxoSmithKline’s pipeline, Recombinant protein and outer membrance vesicle vaccine
. Its studies are mostly in Meningococcal Infections · Meningitis, Meningococcal · Meningitis · Anemia, Sickle Cell, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 130 open or running | phase 3since Apr 2, 2008 | Feb 27, 2006 | none ahead |
| Pfizer | 90 open or running | phase 4since May 14, 2021 | Oct 11, 2006 | none ahead |
| GlaxoSmithKlineits history only | 71 open or running | phase 4since Feb 6, 2018 | Feb 14, 2014 | none ahead |
| Sanofiits history only | 20 open or running | phase 3since Sep 4, 2019 | Sep 4, 2019 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
Men B vaccine GSK3536829
, phase 3, as of Sep 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 11, 2006First study: phase 2 study in HealthyFirst studyNCT00387725 · 127 enrolled · Australia
- Feb 17, 2011Phase 2 study in MeningitisNCT01323270 · 753 enrolled · Finland, Germany, Poland
- May 11, 2011Phase 3 study in HealthyNCT01352845 · 3,301 enrolled · United States, Canada, Denmark and more
- Jan 8, 2013Phase 2 study in Meningitis, MeningococcalNCT01768117 · 13 enrolled · United States
- Apr 3, 2013Phase 3 study in Meningococcal VaccineNCT01830855 · 3,596 enrolled · United States, Canada, Czech Republic and more
- Apr 26, 2017Phase 3 study in Meningococcal VaccineNCT03135834 · 1,610 enrolled · United States, Czechia, Finland and more
- Jun 15, 2020Phase 3 study in Meningococcal VaccineNCT04440163 · 2,431 enrolled · United States, Czechia, Denmark and more
- Nov 20, 2020Phase 2 study in Meningococcal VaccineNCT04645966 · 326 enrolled · Germany, Greece, Spain
- May 14, 2021Phase 4 study in Anemia, Sickle CellNCT04893811 · 53 enrolled · Czechia, Poland, Turkey
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Recombinant protein and outer membrance vesicle vaccine”the company's pipeline, read by Claude · source
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal gr…”NCIt, read by Claude
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal group”NCIt, by rule
Studies
All 9 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04893811Anemia, Sickle Cell · Czechia, Poland, Turkey | 4 | Completed | Sep 6, 2023 | 53 |
| NCT04645966Meningococcal Vaccine · Germany, Greece, Spain | 2 | Terminated | Sep 15, 2022 | 326 |
| NCT04440163Meningococcal Vaccine · United States, Czechia, Denmark and more | 3 | Completed | Jul 24, 2022 | 2,431 |
| NCT03135834Meningococcal Vaccine · United States, Czechia, Finland and more | 3 | Completed | Oct 25, 2022 | 1,610 |
| NCT01830855Meningococcal Vaccine · United States, Canada, Czech Republic and more | 3 | Completed | Apr 2015 | 3,596 |
| NCT01768117Meningitis, Meningococcal · United States | 2 | Completed | Feb 2014 | 13 |
| NCT01352845Healthy · United States, Canada, Denmark and more | 3 | Completed | Feb 2015 | 3,301 |
| NCT01323270Meningitis · Finland, Germany, Poland | 2 | Completed | Oct 8, 2012 | 753 |
| NCT00387725Healthy · Australia | 2 | Completed | Jan 2008 | 127 |
How it is read
Names in the registry
- “rLP2086”, 11 entries
- “rMenB+OMV NZ”, 9 entries
- “Meningococcal B vaccine”, 6 entries
- “rMenB+OMV NZ vaccine”, 3 entries
- “Meningococcal group B vaccine”, 3 entries
Conditions, from the studies’ own filings
- Meningococcal Infections, 10 studies
- Meningitis, Meningococcal, 9 studies
- Meningitis, 2 studies
- Anemia, Sickle Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.